Usefulness and Predictive Capacity of ANI and SPI of the Hemodynamic Response

NCT ID: NCT02608775

Last Updated: 2016-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to investigate the influence of a standardized noxious stimulus on the ANI, SPI and hemodynamic parameters during standard propofol and sufentanil TCI and to see if the ANI and SPI are predictive of a hemodynamic reaction.

In addition the investigators compare the performance of ANI and SPI against one another as well as investigate if ANI or SPI can be used to find the ideal CeSUF for a given patient.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During general anesthesia hypnosis can be monitored routinely using EEG derivates like Bispectral index (BIS), entropy,.… However, monitoring analgesia or more precisely the nociceptive-antinociceptive (analgetic) balance during anesthesia proved more difficult. Clinical signs such as heart rate (tachycardia) or blood pressure (hypertension) are usually observed and used to assess nociception and a patient's autonomic unbalance. During general anesthesia administration of opioids like sufentanil and remifentanil decrease the ANS reactivity to noxious stimulation. Recently two variables based on standard anesthesia monitor equipment have been introduced into clinical practice: the Analgesia Nociception Index (ANI), derived from analysis of the small beat-to-beat oscillations of the heart rate during respiration, the heart rate variability (HRV), and the Surgical Pleth Index (SPI), calculated from the plethysmographic amplitude and heart beat interval.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Tachycardia Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metrodoloris Medical System

Application of a skin electrode

Group Type EXPERIMENTAL

Metrodoloris Medical System

Intervention Type DEVICE

Application of a skin electrode

Aisys® care station, Acertys

Intervention Type DEVICE

Standard photoplethysmography

Aisys® care station, Acertys

SPI calculated from photoplethysmography

Group Type ACTIVE_COMPARATOR

Metrodoloris Medical System

Intervention Type DEVICE

Application of a skin electrode

Aisys® care station, Acertys

Intervention Type DEVICE

Standard photoplethysmography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metrodoloris Medical System

Application of a skin electrode

Intervention Type DEVICE

Aisys® care station, Acertys

Standard photoplethysmography

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ANI monitor SPI monitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* non-pregnant female participants
* ASA II-III
* \>18-65 years
* Weight not exceeding 30% under or above ideal body weight
* Elective intracranial surgery or circumcision.

Exclusion Criteria

* Use concurrent opioid containing drugs
* Use of any autonomic nervous system altering drugs
* History of opioid or alcohol abuse
* Hepatic, renal, metabolic, neuromuscular or cardiovascular disease
* Known allergies to anesthestetic / analgesic drugs
* Use of a peripheral nerve block, penile block
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitair Ziekenhuis Brussel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Veerle Van Mossevelde

Data Nurse

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stef Cornelis, MD

Role: PRINCIPAL_INVESTIGATOR

Universitair Ziekenhuis Brussel

Caroline Vanlersberghe, MD

Role: STUDY_DIRECTOR

Universitair Ziekenhuis Brussel

Jan Poelaert, Prof. MD

Role: STUDY_CHAIR

Universitair Ziekenhuis Brussel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Brussel

Jette, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ANI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.